Application No.: 10/771,552 Docket No.: ALXN-P01-114

CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1-108. (Canceled).

109. (Previously Presented) A method of treating a nitric oxide (NO) deficiency in a subject comprising administering a compound to the subject, the compound being selected from the group consisting of compounds which bind to one or more complement components, compounds which block the generation of one or more complement components and compounds which block the activity of one or more complement components.

110. (Original) A method as in claim 109 wherein the step of administering comprises administering an anti-C5 antibody.

111. (Original) A method as in claim 109 wherein the compound is an anti-C5 antibody selected from the group consisting of h5G1.1-mAb, h5G1.1-scFv and functional fragments of h5G1.1.

112. (Original) A method as in claim 109 wherein the proportion of type III red blood cells of the subject's total red blood cell content is greater than 10%.

113. (Original) A method as in claim 109 wherein the proportion of type III red blood cells of the subject's total red blood cell content is greater than 25%.

114. (Original) A method as in claim 109 wherein the proportion of type III red blood cells of the subject's total red blood cell content is greater than 50%.

115. (Original) A method as in claim 109 wherein the subject's platelet count is greater than 40,000 per microliter.

Application No.: 10/771,552 Docket No.: ALXN-P01-114

116. (Original) A method as in claim 109 wherein the subject's platelet count is greater than 75,000 per microliter.

117. (Original) A method as in claim 109 wherein the subject's platelet count is greater than 150,000 per microliter.

118. (Original) A method as in claim 109 wherein the subject's reticulocyte count is greater than 80 x 10⁹ per liter.

119. (Original) A method as in claim 109 wherein the subject's reticulocyte count is greater than 120 x 10⁹ per liter.

120. (Original) A method as in claim 109 wherein the subject's reticulocyte count is greater than 150 x 10⁹ per liter.

121-171. (Canceled).